Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14960673 | 0.86 | SLC6A3 (0.40) | SLC6A3SLC6A2TDP1L3MBTL1ATM | |
| SCHEMBL14059227 | 0.84 | TDP1 (0.43) | TDP1L3MBTL1ATMNPC1POLB | |
| SCHEMBL14059627 | 0.83 | GAA (0.41) | SLC6A3SLC6A2ATMNPC1POLB | |
| SCHEMBL14059362 | 0.76 | TDP1 (0.35) | SLC6A3SLC6A2TDP1L3MBTL1HSD17B3 | |
| SCHEMBL14059420 | 0.76 | RAB9A (0.39) | NPC1RAB9A | |
| SCHEMBL12797321 | 0.75 | ACHE (0.41) | SLC6A3L3MBTL1ATMNPC1RAB9A | |
| SCHEMBL29292695 | 0.73 | HSD17B3 (0.54) | SLC6A3SLC6A2L3MBTL1ATMNPC1 | |
| SCHEMBL12797306 | 0.73 | ATM (0.39) | TDP1L3MBTL1ATM | |
| SCHEMBL21557572 | 0.72 | NR4A2 (0.38) | SLC6A3L3MBTL1HSD17B3 | |
| SCHEMBL14059233 | 0.72 | SMN1; SMN2 (0.52) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604024-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130131051-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-23 | — | — | US | disclosed |
| US-20130131051-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-23 | — | — | US | disclosed |
| WO-2012162330-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS FOR THE PRODUCTION OF BETA-AMYLOID | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131051-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, SCN2B | SLC6A3 1973/4885SLC6A2 352/4885TDP1 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.